AzTrials
AzTrials

Healthy Adult ParticipantsPhase 1NCT07094932

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09

A Phase 1 study testing TBD09 in people with Healthy Adult Participants, run by Gates Medical Research Institute at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a randomized, double-blind, placebo-controlled, multiple dose trial of TBD09, administered to healthy adult participants to assess safety, tolerability, and pharmacokinetics up to 84 days of fixed daily dosing of TBD09. Read more about this study

Who is it for?
Ages 19 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Adult Participants
What is being tested?
TBD09
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
36 participants
Where
1 siteUnited States
Study dates
3 Sep 2025to 11 Jan 2026
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Is healthy as determined by the Investigator via medical history and clinical examination before enrollment in the trial.
  • Can understand and comply with the trial and site procedures, understand the risks involved in the trial, and provide written informed consent before the first trial-specific procedure
  • Can complete all Screening period evaluations and stay in the clinical research facility for the duration of the inpatient periods of the trial.
  • Has body mass index (BMI) between 18 and 32 kg/m^2 (kilograms per square meter), inclusive, and body weight not less than 50 kg at Screening.
  • Has resting vital signs within the following ranges at Screening and Day -1:
  • Systolic blood pressure (SBP) >= 100 mmHg (millimeters of mercury) and <= 140 mmHg
Show all 24Show fewer
  • Diastolic blood pressure (DBP) >= 60 mmHg and <= 90 mmHg
  • Heart rate between 45 and 100 beats per minute (bpm)
  • Has a 12-lead ECG consistent with normal cardiac conduction and function at Screening, including: HR between 45 and 100 bpm (inclusive); QTcF (QT Interval Corrected Using Fridericia's Formula) ≤450 ms (milliseconds) for males and ≤470 ms for females; QRS interval <120 ms; PR interval <220 ms; and morphology consistent with healthy cardiac conduction.
  • Is a nonsmoker within the previous 90 days before Screening, with a negative urine cotinine test at the time of Screening, and does not use tobacco-containing, or nicotine-containing products, including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, e-cigarettes, nicotine patch, or nicotine gum.
  • Has clinical chemistry (fasted for at least 8 hours), coagulation, and complete urinalysis results at Screening within the reference ranges for the testing laboratory unless the out-of-range results are deemed not clinically significant by the Investigator or designee, and documented as such in source documents.
  • Has negative results for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV Ab) at Screening.
  • Has negative test results for human immunodeficiency virus (HIV) antibody at Screening.
  • Has a negative urine drug screen result at Screening and on Day -1.
  • Has a negative urine alcohol screen result on Day -1.
  • Has a hemoglobin A1c (HbA1c) result less than 5.7% at Screening.
  • Has a thyroid stimulating hormone (TSH) level within the reference range for the testing laboratory at Screening.
  • Has an absolute neutrophil count (ANC) greater than or equal to 2,000 neutrophils per microliter of blood.
  • Has clinical hematology results for total white blood cell count, absolute lymphocyte count, hemoglobin, red blood cell count, and platelet count within the reference ranges for the testing laboratory at Screening.
  • If individual's assigned sex at birth is female, they must have negative urine and serum pregnancy tests at Screening, and be of non-childbearing potential based on either of the following:
  • Is post-menopausal defined as amenorrhea for at least 12 months in absence of any exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the laboratory-defined postmenopausal range, or,
  • Reports being surgically sterilized (ie, tubal ligation, hysterectomy, bilateral oophorectomy/salpingectomy), and provides written documentation [(ie, medical record(s)], where feasible, to document such procedure(s) to the Principal Investigator. The site must make documented attempts to obtain medical records. If records cannot be retrieved, a participant may be enrolled at the Principal Investigator's discretion.
  • If individual is assigned male sex at birth, is not sterilized, and is sexually active with a female partner of childbearing potential, agrees to use condoms from Day -1 through 90 days after the last dose of study drug. They must also agree to not donate sperm during the trial and for 3 months (90 days) after receiving the last dose of study drug.
  • Agrees to follow lifestyle and dietary restrictions.

Who cannot join

  • Has current or past history of a clinically significant cardiovascular, cerebrovascular, respiratory, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease, as determined by the Investigator.
  • Has history of or Screening findings of peripheral neuropathy, such as numbness or abnormal reflexes.
  • Has history of or Screening findings of abnormalities of vision, including corrected visual acuity worse than 20/25 in either eye based on Screening assessment using Snellen chart and Rosenbaum pocket chart, or color vision impairment based on Screening assessment using Ishihara plates. Candidates with ametropia corrected to 20/25 or better do not have to be excluded.
  • Has history of or has clinically relevant cardiovascular disorder, such as heart failure, coronary artery disease, controlled or uncontrolled hypertension, arrhythmia, tachyarrhythmia, prolonged QT syndrome, or presence of symptom(s) strongly suggestive of such a problem, such as exertional chest pressure/pain or unexplained syncope.
  • Had an active malignancy within 5 years from Screening, except basal cell or squamous cell skin cancers. Any history of breast cancer or melanoma will be exclusionary.
  • Has history of any drug abuse within 1 year prior to Screening or has used any hard drugs (such as cocaine, phencyclidine [PCP], natural and synthetic opiates, and amphetamine derivatives) within 1 year prior to Screening. Individuals that have taken an opioid or amphetamine medication within the previous year prior to Screening that was prescribed by a healthcare provider will not be excluded unless they are currently taking the medication at the time of Screening.
Show all 16Show fewer
  • Had any surgical or medical condition or history that, in the opinion of the Investigator, may potentially alter the absorption, metabolism, or excretion of study treatment, such as, but not limited to, gastric bypass, sleeve, banding surgery, or gastric or duodenal ulcers
  • Is taking any of the following prohibited medications or vaccinations:
  • Any prescription or over-the-counter medication, vitamin or dietary supplement, or herbal product within 14 days prior to Day -1.
  • Received any vaccination within 28 days prior to Day -1, including COVID-19 vaccination.
  • Has a contraindication to study drugs or its excipients and/or history of a clinically significant allergic or anaphylactic reaction to any medication.
  • Has participated in other trials involving administration of an investigational drug, vaccine or device within 30 days or 5 half-lives, whichever is longer, before Day -1 for the current trial and during participation in the current trial.
  • Has a positive polymerase chain reaction (PCR) for COVID-19/SARS-CoV-2 on Day -1.
  • Has a condition that the Investigator believes would interfere with the participant's ability to provide written informed consent, comply with trial instructions, or which might confound the interpretation of the trial results or put the participant at undue risk.
  • Has donated blood within 2 months before Screening or planning to donate blood during the trial or within 12 weeks after the final visit.
  • Has previously participated in a clinical trial involving TBD09.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Celerion

    Lincoln, Nebraska, 68502

Other trials in United States

About this study

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09 With an 84-day Period of Fixed Daily Dosing

This is a randomized, double-blind, placebo-controlled, multiple dose trial of TBD09, administered to healthy adult participants to assess safety, tolerability, and pharmacokinetics up to 84 days of fixed daily dosing of TBD09. The trial will be conducted with two cohorts, with participants enrolled in parallel and randomized to receive either TBD09 or placebo.

Being tested
TBD09, Placebo
Keywords
Mycobacterium tuberculosis, TBD09, Fixed daily dosing, Safety, Tolerability, Pharmacokinetics

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TBD09Drug

    TBD09 will be administered orally

  • PlaceboDrug

    Placebo will be administered orally

Study groups in NCT07094932
Study groupRoleWhat they receive
TBD09Active comparatorParticipants will be randomized to receive TBD09 once daily.
Receives: Drug: TBD09
PlaceboPlacebo comparatorParticipants will be randomized to receive placebo once daily.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of participants reporting treatment-emergent adverse events (TEAEs), serious AEs (SAEs), AEs of special interest (AESIs), and AEs leading to withdrawal of study drug after multiple administrations of TBD09.

    Measured: Up to 92 days

  2. Number of participants with clinically significant changes from baseline in safety laboratory measures

    Measured: Day 1 through Day 92

  3. Number of participants with clinically significant changes from baseline in vital signs

    Measured: Day 1 through Day 92

  4. Number of participants with clinically significant changes from baseline in electrocardiogram (ECG) parameters

    Measured: Day 1 through Day 92

Secondary outcomes (8)

  1. Maximum plasma drug concentration (Cmax) of TBD09 in treated participants

    Measured: Day 1

  2. Time to maximal concentration (Tmax) of TBD09 in treated participants

    Measured: Day 1

  3. Area Under the concentration time curve from Zero to 24 hours (AUC 0-24) of TBD09 in treated participants

    Measured: Day 1

  4. Tmax of TBD09 in treated participants

    Measured: Day 84

  5. Cmax of TBD09 in treated participants

    Measured: Day 84

  6. Area Under the concentration time curve from the time of dosing to the time of the last measurable concentration (AUC last) of TBD09 in treated participants

    Measured: Day 84

  7. Minimum plasma drug concentration (Cmin) of TBD09 in treated participants

    Measured: Day 84

  8. Accumulation ratio (area under plasma concentration-time curve over dosing interval [AUCtau] / AUC0-24) of TBD09 in treated participants. Day 84 vs Day 1

    Measured: Day 84

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2025
  2. Study start3 Sep 2025
  3. Primary completion11 Jan 2026
  4. Study completion11 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07094932
Sponsor's protocol ID
Gates MRI-TBD09-103
Status last verified
Oct 2025
First submitted
29 Jul 2025
Last updated
22 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing TBD09 in people with Healthy Adult Participants, run by Gates Medical Research Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of participants reporting treatment-emergent adverse events (TEAEs), serious AEs (SAEs), AEs of special interest (AESIs), and AEs leading to withdrawal of study drug after multiple administrations of TBD09. (time frame: Up to 92 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07094932.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in